galectin-3、HBME-1、CK19及RET在甲状腺肿瘤中的表达情况及其临床价值  

Expressions of Galectin-3,HBME-1,CK19,and RET in Benign and Malignant Thyroid Tumor and Their Clinical Significances

作　　者：黄堃[1] 龚卫东[1] 王南鹏[1] 叶晖[1] 周彦[1] 高庆军[1] 段海松[1] 高荣君[1] 赵代伟[1] 

机构地区：[1]贵阳医学院附属医院甲状腺外科,贵州贵阳550004

出　　处：《中国普外基础与临床杂志》2013年第2期156-160,共5页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：目的分析半乳糖凝集素-3(galectin-3)、人骨髓内皮细胞-1(HBME-1)、细胞角蛋白(CK)19及RET在甲状腺良、恶性肿瘤中的表达情况,探讨其在诊断甲状腺肿瘤中的临床价值。方法收集2009～2012年期间我院甲状腺外科经手术切除的131例甲状腺肿瘤患者的临床病理资料,其中甲状腺恶性肿瘤患者45例,甲状腺良性肿瘤患者86例,应用免疫组织化学方法检测galectin-3、HBME-1、CK19及RET在甲状腺良、恶性肿瘤中的表达情况。结果 galectin-3、HBME-1、CK19及RET在45例甲状腺恶性肿瘤患者中的表达阳性率分别为97.8%(44/45)、88.9%(40/45)、100%(45/45)及71.1%(32/45),均明显高于其在86例甲状腺良性疾病患者中的表达阳性率〔分别为9.3%(8/86)、12.8%(11/86)、37.2%(32/86)及8.1%(7/86)〕,差异均有统计学意义(P<0.05)。galectin-3、HBME-1、CK19及RET诊断甲状腺良、恶性疾病的灵敏度分别为97.8%、88.9%、100%及71.1%,特异度分别为90.7%、87.2%、62.8%及91.9%,诊断符合率分别为93.1%、87.8%、75.6%及84.7%。结论 galectin-3、HBME-1、CK19及RET均在甲状腺恶性肿瘤中表达增强,是甲状腺良、恶性疾病病理诊断中有价值的辅助诊断指标,其中galectin-3对甲状腺恶性肿瘤的诊断有较高的参考价值,联合检测可以较大程度上提高甲状腺癌的诊断率。Objective To analyze the expressions ofgalectin-3, human bone marrow endothelial cell-1 （HBME-1）, cytokeratin （CK） 19, and RET in benign and malignant thyroid tumor and to discuss their clinical significances. Methods The clinicopathologic and immunohistochemical staining data of 131 patients with benign and malignant thyroid tumor were analyzed retrospectively, including 45 patients with malignant thyroid tumor, 86 patients with benign thyroid tumor. The expressions of galectin-3, HBME-1, CK19, and RET in the benign and malignant thyroid tumor were detected by immunohistochemical staining. Results The positive expression rates of the galectin-3, HBME-1, CK19, and RET in the malignant thyroid tumor were 97. 8% （44/45）, 88. 9% （40/45）, 100% （45/45）, and 71.1% （32/45）, respectively, which in the benign thyroid tumor were 9. 3% （8/86）, 12. 8% （11/86）, 37.2% （32/86）, and 8. 1% （7/86）, respectively, the differences were statistically significant （P〈0.05）. The diagnostic sensitivity, specificity, and accordance rates were 97. 8 %, 90. 7%, and 93.1% for the galectin-3, respectively; 88.9%, 87. 2%, and 87.8% for the HBME-1, respec- tively; 100%, 62. 8%, and 75.6% for the CK19, respectively; 71.1%, 91.9%, and 84. 7% for the RET, respectively. Conclusions The expression levels of galectin-3, HBME-1, CK19, and RET in malignant thyroid tumor are significantly higher than those in benign thyroid tumor. Galectin-3, HBME-1, CK19, and RET can be important factors for identifying the benign and malignant tumor and their biological behaviors. Galectin-3 has a high reference value in the diagnosis of thyroid carcinoma.

关 键 词：甲状腺肿瘤 半乳糖凝集素-3 人骨髓内皮细胞-1 细胞角蛋白19 RET 免疫组织化学 

分 类 号：R736.1[医药卫生—肿瘤]